Compare TCBS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBS | XLO |
|---|---|---|
| Founded | 1934 | 2016 |
| Country | United States | United States |
| Employees | N/A | 76 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 49.0M |
| IPO Year | 2021 | 2021 |
| Metric | TCBS | XLO |
|---|---|---|
| Price | $16.91 | $8.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 809.0 | ★ 30.5K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 327.27 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $16.79 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $15.10 | $0.46 |
| 52 Week High | $20.00 | $9.25 |
| Indicator | TCBS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 65.79 |
| Support Level | $16.79 | $0.62 |
| Resistance Level | $17.13 | $9.22 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | -0.07 | -0.28 |
| Stochastic Oscillator | 9.88 | 20.65 |
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.